Navigation Links
Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
Date:3/4/2008

TUSTIN, Calif., March 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the third quarter of fiscal year 2008 on March 11, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the quarter and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/8:30 a.m. PDT.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
9. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
10. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
11. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... , July 1, 2015   Neuraltus Pharmaceuticals, ... development of groundbreaking drugs to treat neurodegenerative diseases ... that Robert G. Miller , M.D., Director of ... Health,s California Pacific Medical Center in San Francisco, has ... for $1.5 million to help fund a Phase ...
(Date:7/1/2015)... Isagenix International, a leading global health and ... Silver, and three Bronze Stevie® Awards at the 2015 ... Chicago this month.The American Business Awards ... in the U.S. "Winning is a ... leaders, cultivating talent, creating a unified team, and crafting ...
(Date:7/1/2015)... , July 1, 2015 ... technology will ... s evidence-based clinical s olutions suite   ... technical and medical information products and services, announced today the ... clinical decision support (CDS) technology company. InferMed,s Arezzo ...
(Date:7/1/2015)... ... 01, 2015 , ... NEMA 4 (IP66) Medical Joysticks can ... Joysticks have an impermeable molecular barrier protection against bio-hazardous agents. Original Equipment ... increase healthcare worker safety and reduce financial costs. , CTI Electronics announces a ...
Breaking Biology Technology:Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 2Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 3Elsevier Acquires InferMed, Provider of Clinical Decision Support Technology 4Sanitized Medical Joysticks for a Safer and Healthier Work Environment 2
... Today BioSpace, the leading life sciences employment ... Hotbed Campaign, marking the campaign,s eleventh edition. ... highlights companies in the Mid-Atlantic biotechnology, pharmaceutical and ... included on an electronic and print map promoting ...
... 26, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: ... submitted a New Drug Application (NDA) to the United ... inhaled migraine drug for the potential acute treatment of ... approximately 30 million people in the United States suffer ...
... the issue of data overload from next-generation sequencers, Life ... its LifeScope™ 2.0 Genomic Analysis Software , a significantly ... to study human disease such as cancer. ... generation sequencing instrument can generate nearly 200 gigabytes of genomic ...
Cached Biology Technology:MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 2MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 3MAP Pharmaceuticals Submits New Drug Application to FDA for LEVADEX® Orally Inhaled Migraine Drug 4Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 2Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 3Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 4Life Technologies Simplifies, Organizes and Speeds Analysis of Genomic Data Through Launch of New LifeScope Bioinformatics Software 5
(Date:6/30/2015)... To bolster its efforts and commitment to fighting cyber fraud, ... of two new team members. Dimitri ... Raviv will act as head of strategic alliances. These ... the most secure solutions for the enterprise market. ... a provider of security and management products, which was acquired ...
(Date:6/25/2015)... 25, 2015  Imagine a tool specifically designed to ... happier life. That,s exactly what USANA,s True Health ... cutting-edge, portable health program provides a personalized approached to ... improve your lifestyle and nutrition. At ... Wednesday night, USANA,s THA was honored with the Industry ...
(Date:6/24/2015)... 22, 2015 Research ... of the "Huawei Ascend Mate 7 Fingerprint ... their offering. Huawei,s technological choice for ... direction than Apple,s and Samsung,s one. The Ascend ... by Fingerprint Cards, a main actor in capacitive ...
Breaking Biology News(10 mins):HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 2HYPR Corp. Expands Biometric Authentication Team with Enterprise All Stars 3@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2
... it was demonstrated for the first time that long ... performed clinically) results in a reactivation of the major ... loop via ERK1/2. This reactivation of Akt limits quite ... presenting constitutively active K-Ras activity (both through K-RAS mutation ...
... , Jan. 7, 2014 from ShowStoppers @ CES 2014 ... X personalized, rechargeable vaporizer unit will become available to consumers ... 2014 holiday retail season. There will be a working prototype ... ShowStoppers at CES 2014, Booth # A5. In ...
... , Jan. 7, 2014 DigitalPersona, Inc., ... today announced that its TouchChip® TCS1 sensor is ... certified by the Ministry of Public Security under ... T 1011-2012 for the China Resident Identity Card.  ...
Cached Biology News:Vapor Corp. Unveils E-Cigarette Industry's First Biometric Technology 2Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 2Fingerprint Readers with DigitalPersona Silicon-based Sensors Certified for China Resident Identity Card 3
... 45° Fixed Angle rotor for ... CL2, Centra CL3/CL3R, HN-SII or ... style rotor accepts 15 mL ... disposable conical tubes as well ...
... microfractionaction, spotting and preparation for MS analysis. ... eluent can be accurately and continuously spotted ... Matrix solutions can be added automatically. This ... for MALDI-TOF-MS measurements. By using it in ...
Glycerokinase; from Bacillus stearothermophilus...
PTFE/red rubber septum silver aluminum seal ,11 mm seal diam. ...
Biology Products: